These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 9529518)

  • 1. Sibutramine for obesity.
    Med Lett Drugs Ther; 1998 Mar; 40(1022):32. PubMed ID: 9529518
    [No Abstract]   [Full Text] [Related]  

  • 2. Sibutramine-associated adverse effects: a practical guide for its safe use.
    Florentin M; Liberopoulos EN; Elisaf MS
    Obes Rev; 2008 Jul; 9(4):378-87. PubMed ID: 18034790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Obesity drug sibutramine (Meridia): hypertension and cardiac arrhythmias.
    Wooltorton E
    CMAJ; 2002 May; 166(10):1307-8. PubMed ID: 12041851
    [No Abstract]   [Full Text] [Related]  

  • 4. The clinical effectiveness and cost-effectiveness of sibutramine in the management of obesity: a technology assessment.
    O'Meara S; Riemsma R; Shirran L; Mather L; ter Riet G
    Health Technol Assess; 2002; 6(6):1-97. PubMed ID: 12000688
    [No Abstract]   [Full Text] [Related]  

  • 5. Diet drug helps keep weight off.
    Health News; 2001 Feb; 7(2):6. PubMed ID: 11232119
    [No Abstract]   [Full Text] [Related]  

  • 6. Sibutramine: an Australian analysis of reported adverse effects.
    Prescrire Int; 2007 Jun; 16(89):114. PubMed ID: 17590911
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial.
    Sramek JJ; Leibowitz MT; Weinstein SP; Rowe ED; Mendel CM; Levy B; McMahon FG; Mullican WS; Toth PD; Cutler NR
    J Hum Hypertens; 2002 Jan; 16(1):13-9. PubMed ID: 11840225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. European Medicines Agency withdrawal for sibutramine.
    Galhardo J; Davis N; Matthai S; Shield JP
    Arch Dis Child; 2010 Oct; 95(10):856. PubMed ID: 20573736
    [No Abstract]   [Full Text] [Related]  

  • 9. Sibutramine: new preparation. Slight weight loss; but also a slight rise in blood pressure ..
    Prescrire Int; 2001 Oct; 10(55):140-5. PubMed ID: 11824428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of sibutramine in 2225 subjects with cardiovascular risk factors: short-term, open-label, observational study.
    Gaciong Z; Placha G
    J Hum Hypertens; 2005 Sep; 19(9):737-43. PubMed ID: 15905888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does drug therapy of obesity have a future?
    Trakas K; Leiter L; Shear NH
    Can J Clin Pharmacol; 2000; 7(3):133-4. PubMed ID: 11044757
    [No Abstract]   [Full Text] [Related]  

  • 12. [The anti-obesity drug sibutramine for overweight diabetic patients. "Blood pressure is not elevated")].
    Matiba B
    MMW Fortschr Med; 2002 Jul; 144(27-28):16; author reply 17. PubMed ID: 12198873
    [No Abstract]   [Full Text] [Related]  

  • 13. Cardiovascular effects of sibutramine.
    Pisarik P
    Pediatrics; 2007 Oct; 120(4):930-1; author reply 931-2. PubMed ID: 17908786
    [No Abstract]   [Full Text] [Related]  

  • 14. [Sibutramine, an upcoming drug for weight loss acting on energy consumption and energy expenditure].
    Astrup A
    Acta Med Austriaca; 1998; 25(4-5):146-9. PubMed ID: 9879391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors.
    McMahon FG; Weinstein SP; Rowe E; Ernst KR; Johnson F; Fujioka K;
    J Hum Hypertens; 2002 Jan; 16(1):5-11. PubMed ID: 11840224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients.
    Derosa G; Cicero AF; Murdolo G; Piccinni MN; Fogari E; Bertone G; Ciccarelli L; Fogari R
    Diabetes Obes Metab; 2005 Jan; 7(1):47-55. PubMed ID: 15642075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term pharmacotherapy for obesity.
    Klein S
    Obes Res; 2004 Dec; 12 Suppl():163S-6S. PubMed ID: 15687412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular effects of sibutramine in the treatment of obese adolescents: results of a randomized, double-blind, placebo-controlled study.
    Daniels SR; Long B; Crow S; Styne D; Sothern M; Vargas-Rodriguez I; Harris L; Walch J; Jasinsky O; Cwik K; Hewkin A; Blakesley V;
    Pediatrics; 2007 Jul; 120(1):e147-57. PubMed ID: 17576783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [No progress without the physician in therapy of obesity].
    Schmidt H; Plauth M
    MMW Fortschr Med; 2000 Jan; 142(4):35-6. PubMed ID: 10850095
    [No Abstract]   [Full Text] [Related]  

  • 20. Sibutramine in the management of obesity.
    Brunton S
    J Fam Pract; 2003 Aug; 52(8):635. PubMed ID: 12899819
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.